Thorium Th 227 Pelgifatamab Corixetan

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A radioimmunoconjugate consisting of pelgifatamab, a monoclonal antibody targeting the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), conjugated to the chelator corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 pelgifatamab corixetan, the pelgifatamab moiety targets and specifically binds to PSMA on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing PSMA. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.

**Synonyms:** - 227Th-Pelgifatamab Corixetan - BAY 2315497 - BAY-2315497 - BAY2315497 - PSMA-TTC BAY 2315497 - PSMA-targeted Thorium-227 Conjugate BAY-2315497 - Targeted Thorium Conjugate BAY 2315497 - Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497 - Thorium Th 227 Monoclonal Antibody BAY 2315497 - Thorium-227 Anti-PSMA Monoclonal Antibody BAY 2315497 - Thorium-227 Labeled Antibody-chelator Conjugate BAY 2315497 - Thorium-227 Labeled Immunoconjugate BAY-2315497